



LITERATURA

1. Češková E. Postavení aripirazolu v klinické praxi. *Čes a slov Psychiatrie* 2011; 107: 110–114.
2. Mohr P, Kopeček M, Brunovský M, et al. Kariprazin in *Klinická psychofarmakologie*. Maxdorf, 2017, pp 161–164.
3. Ceskova E, Silhan P. Novel treatment options in depression and psychosis. *Neuropsychiatr Dis Treat* 2018; 14: 741–747.
4. Citrome L. The ABC's of dopamine receptor partial agonists - aripirazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. *Int J Clin Pract* 2015; 69: 1211–1220.
5. Maeda K, Sugino H, Akazawa H, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. *J Pharmacol Exp Ther* 2014; 350: 589–604.
6. Mohr P, Kopeček M, Brunovský M, et al. Brexpiprazol, in *Klinická psychofarmakologie*. Maxdorf, 2017, pp 135–138.
7. Stahl SM. Mechanism of action of brexpiprazole: comparison with aripirazole. *CNS Spectr* 2016; 21:1–6.
8. Citrome L, Ota A, Nagamizu K, et al. The effect of brexpiprazole (OPC-34712) and aripirazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. *Int Clin Psychopharmacol* 2016; 31: 192–201.
9. Citrome L. Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder. Absolute Risk Increase and Number Needed to Harm. *J Clin Psychopharmacol* 2017; 37: 138–147.
10. Stoner SC. Management of serious cardiac adverse effects of antipsychotic medications. *Ment Health Clin* 2017; 7: 246–254.
11. Polcwiartek C, Sneider B, Graff C, et al. The cardiac safety of aripirazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. *Psychopharmacology (Berl)* 2015; 232: 3297–3308.
12. Chattopadhyay A, Frey S, Green G. Bifeprunox versus placebo for schizophrenia. *Cochrane Database Syst Rev* 2016; 10: CD012029.
13. Maeda K, Lerdrup L, Sugino H, et al. Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. *J Pharmacol Exp Ther* 2014; 350: 605–614.
14. Rexulti (brexpiprazole) [product information]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd 2015.
15. I. OPDC: PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia. [cited 2018 Nov 11]. Available from: <http://clinicaltrials.gov/show/NCT01854944>
16. Correll CU, Skuban A, Ouyang J, et al. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. *Am J Psychiatry* 2015; 172: 870–880.
17. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. *Schizophr Res* 2015; 164: 127–135.
18. Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study. *Psychiatry Clin Neurosci* 2018; 72: 692–700.
19. Kishi T, Oya K, Matsui Y, et al. Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. *Neuropsychiatr Dis Treat* 2018; 14: 2519–2530.
20. Fleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. *Int J Neuropsychopharmacol* 2017; 20: 11–21.
21. Thase ME, Youakim JM, Skuban A, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. *J Clin Psychiatry* 2015; 76: 1224–1231.
22. Thase ME, Youakim JM, Skuban A, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. *J Clin Psychiatry* 2015; 76: 1232–1240.
23. Hobart M, Skuban A, Zhang P, et al. A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder. *J Clin Psychiatry* 2018; 79.
24. Bauer M, Hefting N, Lindsten A, et al. A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder. *Acta Neuropsychiatr* 2018; 1–9.
25. Lepola U, Hefting N, Zhang D, et al. Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study. *Int J Geriatr Psychiatry* 2018; 33: 1403–1410.
26. Otsuka Pharmaceutical Development & Commercialization I. A study of two fixed-doses of brexpiprazole in the treatment of subjects with agitation associated with dementia of the Alzheimer's type [Internet] Bethesda (MD): National Library of Medicine (US); 2000 [cited 2018 Nov 11]. Available from: <http://clinicaltrials.gov/show/NCT01862640>;
27. Rexulti, brexpiprazole (summary of product characteristics). the European Medicines Agency <http://www.ema.europa.eu>. 2018.